secwatch.observer — SEC 8-K summary
======================================

Issuer:     Armata Pharmaceuticals, Inc. (ARMP)
CIK:        0000921114
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001558370-25-007752
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Armata Q1 net loss $6.5M, cash $11.7M; AP-SA02 Phase 1b/2a topline due H1 2025
------------------------------------------------------------------------------

- Net loss of $6.5M ($0.18 basic EPS) vs $25.0M loss in Q1 2024; includes $5.2M non-cash gain on convertible loan.
- Cash and equivalents $11.7M at March 31, 2025, up from $9.3M at Dec 31, 2024; 36.2M shares outstanding.
- Topline results from Phase 1b/2a diSArm study of intravenous AP-SA02 for S. aureus bacteremia expected in first half 2025.
- Received additional $4.65M non-dilutive DoD/MTEC funding to support AP-SA02 Phase 2 close-out and FDA end-of-Phase 2 meeting.
- Entered $10.0M secured credit agreement with Innoviva; existing Innoviva credit agreements extended to March 12, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921114/000155837025007752/0001558370-25-007752-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921114/000155837025007752/armp-20250514x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-007752

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer